MENU
+Compare
DMAC
Stock ticker: NASDAQ
AS OF
Apr 3, 03:10 PM (EDT)
Price
$3.69
Change
-$0.28 (-7.07%)
Capitalization
169.71M

DMAC DiaMedica Therapeutics Forecast, Technical & Fundamental Analysis

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DMAC with price predictions
Apr 02, 2025

DMAC in +5.64% Uptrend, rising for three consecutive days on March 17, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DMAC advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DMAC as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DMAC moved below its 50-day moving average on March 18, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DMAC crossed bearishly below the 50-day moving average on March 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DMAC entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.168) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DMAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DMAC is expected to report earnings to rise 11.11% to -20 cents per share on May 20

DiaMedica Therapeutics DMAC Stock Earnings Reports
Q1'25
Est.
$-0.20
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.03
Q1'24
Beat
by $0.02
The last earnings report on March 17 showed earnings per share of -18 cents, missing the estimate of -17 cents. With 45.51K shares outstanding, the current market capitalization sits at 169.71M.
A.I. Advisor
published General Information

General Information

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
301 Carlson Parkway
Phone
+1 763 496-5454
Employees
19
Web
https://www.diamedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDTTX22.19N/A
N/A
Fidelity Advisor Capital Development A
DCGTX17.06N/A
N/A
Jackson Square SMID-Cap Growth IS
FEAAX48.58N/A
N/A
Fidelity Advisor Emerging Asia A
SGPSX74.62N/A
N/A
ProFunds Small Cap Growth Svc
TCPWX10.34N/A
N/A
Transamerica Capital Growth R6

DMAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+5.60%
WHWK - DMAC
42%
Loosely correlated
N/A
VTGN - DMAC
28%
Poorly correlated
+2.14%
AVXL - DMAC
26%
Poorly correlated
+6.73%
PCVX - DMAC
26%
Poorly correlated
+4.53%
HUMA - DMAC
26%
Poorly correlated
-2.01%
More